Revisiting Dendreon : A Story Unchanged Print E-mail
By Brian Wilson-Lead Contributor   
Sunday, 08 December 2013 23:43
After Q1 2013 (link) we entertained the thought of seeing Dendreon Corporation (NASDAQ: DNDN) at $2/share before 2016, which led to some backlash.
Read more...
 
A Bull/Bear Outline for the Unilife Debate Print E-mail
By Brian Wilson-Lead Contributor   
Wednesday, 04 December 2013 22:59
In our previous article (link) on Unilife (NASDAQ: UNIS), published on November 27th 2013, we predicted that UNIS would probably break 100% in YTD gains.
Read more...
 
Soligenix: 10 Catalysts to Look for in 2014 Print E-mail
By Brian Wilson - Lead Contributor   
Wednesday, 04 December 2013 13:33
We are revisiting the vaccine and drug developer Soligenix ahead of 9 events that will occur in 2014 – all of which are important to the company and its investors.
Read more...
 
Big Opportunities for Sorrento after Acquisition of ADC Tech Print E-mail
By Mary Davila   
Sunday, 01 December 2013 22:56
After some new and aggressive developments, we are once again taking a look at Sorrento Therapeutics (NASDAQ: SRNE).
Read more...
 
Unilife May Finish the Year With >100% YTD Gains Print E-mail
By Brian Wilson - Lead Contributor   
Wednesday, 27 November 2013 10:57
Unilife Corp (NASDAQ: UNIS), a company with a decently large pipeline of customizable injection devices, saw another big rally this year after the company announced – on November 20th 2013 (link) – that the company signed a long-term supply agreement with the London-based generic pharmaceutical company Hikma Pharmaceuticals (LSE:HIK)
Read more...
 
PCSK9 Dampens Appetite for Aegerion Pharma Stock Print E-mail
By Brian Wilson - Lead Contributor   
Monday, 25 November 2013 10:45
Investors who follow Aegerion Pharmaceuticals (NASDAQ: AEGR) may have noticed that it has been tested by the bears a few times in recent weeks.
Read more...
 
OPKO: Expecting More Strength in 2014 on Pipeline Developments Print E-mail
By Brian Wilson-Lead Contributor   
Friday, 22 November 2013 01:26
It hasn't been a good year for short sellers betting against the rapidly growing healthcare conglomerate OPKO Health (NYSE: OPK) and its CEO/Chairman - Dr. Phillip Frost.
Read more...
 
Ampio: Anticipating Data for Exciting DME Therapy, Optina Print E-mail
By Brian Wilson - Lead Contributor   
Thursday, 21 November 2013 15:05
Ampio Pharmaceuticals (NASDAQ: AMPE) is a late stage pharmaceutical company that has been focusing on the clinical development of Ampion and Optina – two drugs that target very large indications. At time of writing, the company is trading at a $327 M valuation, with about $32 M in cash as of September 30th 2013.
Read more...
 
IntelliPharmaCeutics Rips 162% Higher on an FDA Approval Print E-mail
By Brian Wilson-Lead Contributor   
Wednesday, 20 November 2013 08:57
Yesterday’s trading was overwhelmingly bullish for the controlled release and targeted drug developer Intellipharmaceutics (NASDAQ: IPCI) after the FDA gave final approval to the company’s dexmethylphenidate hydrochloride extended-release capsules at the 15 and 30 mg doses on Monday night.
Read more...
 
2 Pharmas Presenting at 55th ASH Meeting Print E-mail
By Brian Wilson-Lead Contributor   
Sunday, 17 November 2013 23:22
As a close follower of the hematologic cancer developers, I wanted to point out the following important data releases that are scheduled for the upcoming 55th annual American Society of Hematology Meeting – to be held December 7-10, 2013 in New Orleans.
Read more...
 
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>

Page 17 of 56

Newsletter